Janssen Expands Research & Development Presence with Major Investment in South San Francisco

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced a significant investment to expand the presence and capabilities of Janssen Research & Development, LLC, in the San Francisco Bay Area. Reflecting the significant impact of Janssen and its research and development strategic direction on the mission of innovation at Johnson & Johnson, this investment will support the leasing and construction of a state-of-the-art R&D facility in the global innovation center of South San Francisco, CA. Janssen BioPharma, Inc. executed the lease within the Healthpeak Properties, Inc., South San Francisco project at The Shore at Sierra Point, Brisbane, CA.

With this investment, Janssen will continue to enable world-class discovery, enhance collaboration opportunities with innovation partners and integrate data science in all aspects of research and development. Moreover, this expansion will allow Janssen to bridge key interdisciplinary capabilities, such as biology and data science, to fuel a step-change in how it creates medicines. San Francisco is consistently ranked among the top cities globally for biologics development and life sciences research. The area also leads the world in "bilingual" data science talent, namely those individuals who are conversant in both life sciences and technology.

"As a well-established global technology and entrepreneurial hub and home to a wide array of pharmaceutical and biotechnology companies, the South San Francisco Bay Area is an ideal location to expand our R&D capabilities and global footprint," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development. "Expanding our R&D presence in South San Francisco will better enable deep partnerships with biotechnology companies, universities and investors in the region. This is one important step to enable us to accelerate the growth of our portfolio of innovative products ultimately to deliver better health outcomes for patients around the world. We look forward to being an even greater contributor to and participant in one of the most vibrant scientific ecosystems in the world."

Janssen personnel at this new facility will focus on infectious and retinal diseases, data science and emerging modalities within discovery, product development and supply. The expanded facility is projected to more than double Janssen's presence in South San Francisco and is anticipated to be fully operational in 2022, upon completion of construction.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.